Feifei Nan

1.5k total citations
38 papers, 794 citations indexed

About

Feifei Nan is a scholar working on Pathology and Forensic Medicine, Oncology and Immunology. According to data from OpenAlex, Feifei Nan has authored 38 papers receiving a total of 794 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pathology and Forensic Medicine, 23 papers in Oncology and 11 papers in Immunology. Recurrent topics in Feifei Nan's work include Lymphoma Diagnosis and Treatment (26 papers), Immune Cell Function and Interaction (8 papers) and CAR-T cell therapy research (7 papers). Feifei Nan is often cited by papers focused on Lymphoma Diagnosis and Treatment (26 papers), Immune Cell Function and Interaction (8 papers) and CAR-T cell therapy research (7 papers). Feifei Nan collaborates with scholars based in China and United States. Feifei Nan's co-authors include Yu Chang, Zhaoming Li, Huanle Zhang, Xiaorui Fu, Lei Zhang, Jingjing Wu, Zhenchang Sun, Xinhua Wang, Mingzhu Huang and Yuqing Li and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Feifei Nan

38 papers receiving 789 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Feifei Nan China 16 465 399 275 246 137 38 794
Chengfeng Bi China 12 256 0.6× 325 0.8× 97 0.4× 162 0.7× 100 0.7× 29 536
Elisa Pellegrino Italy 12 273 0.6× 342 0.9× 153 0.6× 325 1.3× 153 1.1× 21 742
James Q. Wang Australia 9 392 0.8× 579 1.5× 288 1.0× 222 0.9× 149 1.1× 12 904
Markus Möbs Germany 19 303 0.7× 250 0.6× 240 0.9× 237 1.0× 116 0.8× 42 802
Kedar Inamdar United States 15 253 0.5× 276 0.7× 141 0.5× 393 1.6× 73 0.5× 39 772
Hong Yi Wang United States 7 531 1.1× 205 0.5× 383 1.4× 175 0.7× 71 0.5× 12 791
Helle Toldbod Denmark 9 405 0.9× 513 1.3× 244 0.9× 191 0.8× 55 0.4× 13 804
Y. Terui Japan 14 208 0.4× 183 0.5× 221 0.8× 330 1.3× 50 0.4× 29 687
Takashi Akasaka Japan 15 194 0.4× 323 0.8× 120 0.4× 222 0.9× 107 0.8× 45 660
S. Öhl Germany 13 234 0.5× 378 0.9× 179 0.7× 216 0.9× 114 0.8× 19 778

Countries citing papers authored by Feifei Nan

Since Specialization
Citations

This map shows the geographic impact of Feifei Nan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Feifei Nan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Feifei Nan more than expected).

Fields of papers citing papers by Feifei Nan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Feifei Nan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Feifei Nan. The network helps show where Feifei Nan may publish in the future.

Co-authorship network of co-authors of Feifei Nan

This figure shows the co-authorship network connecting the top 25 collaborators of Feifei Nan. A scholar is included among the top collaborators of Feifei Nan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Feifei Nan. Feifei Nan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sun, Zhenchang, Wenjuan Wan, Xudong Zhang, et al.. (2022). The clinical characteristics and prognostic factors of 410 patients with natural killer/T-cell lymphoma. Journal of Cancer Research and Clinical Oncology. 148(12). 3449–3459. 1 indexed citations
2.
Yu, Hui, Xiaorui Fu, Lei Zhang, et al.. (2021). Clinical analysis of patients with primary and secondary extranodal natural killer/T‐cell lymphoma of central nervous system. Hematological Oncology. 41(2). 267–274. 2 indexed citations
3.
Li, Ling, Lei Zhang, Xin Li, et al.. (2021). Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study. Indian Journal of Hematology and Blood Transfusion. 38(1). 42–50. 2 indexed citations
4.
5.
Zhang, Lei, Ling Li, Xin Li, et al.. (2020). <p>Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases</p>. OncoTargets and Therapy. Volume 13. 7189–7197. 11 indexed citations
6.
Li, Ling, Lei Zhang, Xiaorui Fu, et al.. (2020). <p>Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study</p>. Drug Design Development and Therapy. Volume 14. 275–284. 7 indexed citations
7.
Zhang, Lei, Xin Li, Ling Li, et al.. (2020). Research on the midterm efficacy and prognosis of patients with diffuse large B-cell lymphoma by different evaluation methods in interim PET/CT. European Journal of Radiology. 133. 109301–109301. 10 indexed citations
8.
9.
Chang, Yu, Xiaorui Fu, Meng Cui, et al.. (2019). Activated hippo signal pathway inhibits cell proliferation and promotes apoptosis in NK/T cell lymphoma cells. Cancer Medicine. 8(8). 3892–3904. 25 indexed citations
10.
Yan, Jiaqin, Junhui Zhang, Xudong Zhang, et al.. (2018). AEG-1 is involved in hypoxia-induced autophagy and decreases chemosensitivity in T-cell lymphoma. Molecular Medicine. 24(1). 35–35. 18 indexed citations
11.
Zhang, Xudong, Xiaorui Fu, Meng Dong, et al.. (2018). Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells?. Cancer Cell International. 18(1). 150–150. 5 indexed citations
12.
Wu, Jingjing, Lingling Duan, Lei Zhang, et al.. (2018). Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial. Journal of Neuro-Oncology. 140(2). 427–434. 19 indexed citations
13.
14.
Li, Ling, Ken H. Young, Lei Zhang, et al.. (2017). Efficacy and Safety of Novel Targeted Drug' Apatinib in Relapse or Refractory Non-Hodgkin Lymphoma: An Open Label, Single-Armed, Exploratory Study. Blood. 130. 1548–1548. 2 indexed citations
15.
Li, Ling, Wenjing Duan, Lei Zhang, et al.. (2017). The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T‐cell lymphoma with analysis of biomarkers. British Journal of Haematology. 178(5). 772–780. 21 indexed citations
16.
Cui, Yingying, Xin Li, Zhenchang Sun, et al.. (2015). Safety and efficacy of low-dose pre-phase before conventional-dose chemotherapy for ulcerative gastric diffuse large B-cell lymphoma. Leukemia & lymphoma. 56(9). 2613–2618. 11 indexed citations
17.
Cui, Yingying, Zhenchang Sun, Xin Li, et al.. (2015). Expression and clinical significance of cyclooxygenase-2 and interleukin-32 in primary gastric B-cell lymphoma. Oncology Letters. 11(1). 693–698. 15 indexed citations
18.
Li, Zhaoming, Tian Tian, Xiao Hu, et al.. (2014). Targeting Six1 by lentivirus-mediated RNA interference inhibits colorectal cancer cell growth and invasion.. PubMed. 7(2). 631–9. 20 indexed citations
19.
Li, Zhaoming, Tian Tian, Xiao Hu, et al.. (2013). Six1 mediates resistance to paclitaxel in breast cancer cells. Biochemical and Biophysical Research Communications. 441(3). 538–543. 31 indexed citations
20.
Huang, Mingzhu, Yuqing Li, Huanle Zhang, & Feifei Nan. (2010). Breast cancer stromal fibroblasts promote the generation of CD44+CD24- cells through SDF-1/CXCR4 interaction. Journal of Experimental & Clinical Cancer Research. 29(1). 80–80. 93 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chengfeng Bi Breakdown of academic impact, for papers by Elisa Pellegrino Breakdown of academic impact, for papers by James Q. Wang Breakdown of academic impact, for papers by Markus Möbs Breakdown of academic impact, for papers by Kedar Inamdar Breakdown of academic impact, for papers by Hong Yi Wang Breakdown of academic impact, for papers by Helle Toldbod Breakdown of academic impact, for papers by Y. Terui Breakdown of academic impact, for papers by Takashi Akasaka Breakdown of academic impact, for papers by S. Öhl
Rankless by CCL
2026